Sublingual immunotherapy for peanut allergy: a randomized, double-blind, placebo-controlled multicenter trial.

@article{Fleischer2013SublingualIF,
  title={Sublingual immunotherapy for peanut allergy: a randomized, double-blind, placebo-controlled multicenter trial.},
  author={David M. Fleischer and Arvil Wesley Burks and Brian P. Vickery and Amy M Scurlock and Robert B. Wood and Stacie M. Jones and Scott H. Sicherer and Andrew H. Liu and Donald E Stablein and Alice K. Henning and Lloyd Hitoshi Mayer and Robert W Lindblad and Marshall Plaut and Hugh A Sampson},
  journal={The Journal of allergy and clinical immunology},
  year={2013},
  volume={131 1},
  pages={119-27.e1-7}
}
BACKGROUND There are presently no available therapeutic options for patients with peanut allergy. OBJECTIVE We sought to investigate the safety, efficacy, and immunologic effects of peanut sublingual immunotherapy (SLIT). METHODS After a baseline oral food challenge (OFC) of up to 2 g of peanut powder (approximately 50% protein; median successfully consumed dose [SCD], 46 mg), 40 subjects, aged 12 to 37 years (median, 15 years), were randomized 1:1 across 5 sites to daily peanut or placebo… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 81 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 50 references

Similar Papers

Loading similar papers…